


The following is a complete listing of all claims in the application, with an indication of the status of each:

**Listing of claims:**

1. (Currently amended) A method of vaccinating an animal or human in need thereof, comprising the steps of:

providing said animal or human, via mucous membranes of said animal or human, with an antigen; and

providing said animal or human, via mucous membranes of said animal or human, with an adjuvant in the form of ~~The use of~~ a lipopeptide or lipoprotein of the structure (I)



where

R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, are C<sub>7-25</sub>-alkyl, C<sub>7-25</sub>-alkenyl or C<sub>7-25</sub>-alkynyl,

X is S, O or CH<sub>2</sub>,

R<sub>3</sub> and R<sub>4</sub> are independently of one another H or methyl and

Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used,

and the asymmetric carbon atom marked with \* as the absolute R configuration, according to the Cahn-Inhold-Prelog rule, when X is S (sulfur);

~~as mucosal adjuvant in therapeutic or prophylactic vaccination via the mucous membranes.~~

2. (Currently amended) The method of use as claimed in claim 1, wherein ~~characterized in that~~

the amino acid sequence Y is preferably selected from

- a) GQTNT (SEQ ID NO: 1)
- b) SKKKK (SEQ ID NO: 2)
- c) GNNDENISFKEK (SEQ ID NO: 3 and
- d) GQTDNNSQSAAPGSGTTNT.(SEQ ID NO: 4).


3. (Currently amended) The method of use as claimed in claim 1, wherein characterized in that the lipoprotein or lipopeptide of structure (I) is an S-[2, 3-bisphalmitoyloxy(2R)propyl]cysteiny-peptide, where the peptide is a physiologically tolerated amino acid sequence which consists of 12 to 25 amino acid residues and is preferably not immunogenic in the species used.

4. (Currently amended) The method of use as claimed in claim 1, wherein characterized in that the mucosal adjuvant is present in a preparation with the antigen actual vaccine component, and wherein said providing steps are performed simultaneously by an administration route selected from the group consisting of which is intended for intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal or intraurethral administration or administration into the milk ducts of the female breast.

5. (Currently amended) The method of use as claimed in claim 1, wherein characterized in that the mucosal adjuvant is present in a kit for coadministration with the antigen, and wherein each of said providing steps are performed by an administration route a vaccine into the milk ducts of the female breast selected from the group consisting of ,by the intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal and or intraurethral route.

6. (Currently amended) A method of vaccinating an animal or human in need thereof, comprising the steps of:

providing said animal or human with an antigen component by a non-mucosal route; and  
providing said animal or human with an adjuvant in the form of The use of a lipopeptide or lipoprotein of the general structure (I)



where

R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, are C<sub>7-25</sub>-alkyl, C<sub>7-25</sub>-alkenyl or C<sub>7-25</sub>-alkynyl, X is S, O or CH<sub>2</sub>,

R<sub>3</sub> and R<sub>4</sub> are independently of one another H or methyl and

Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used, and the asymmetric carbon atom marked with \* as the absolute R configuration, according to the Cahn-Ingold-Prelog rule, when X is S (sulfur), excepting an S-(2,3-diacetyloxypropyl)cysteinepeptide of the sequence DhcGNNDENISFKEK (SEQ ID NO: 3), where at least one of the following provisos apply

i) N-terminally the amino acids acid at position positions 2 is absent,

ii) N-terminally the amino acid at position and, where appropriate, 3 are is absent, and/or

iii) C-terminally 1 to 2 amino acids are ~~may be deleted;~~ as adjuvant in a non-mucosal vaccination.

7. (Currently amended) The method of claim 6 wherein said providing an animal or human with an adjuvant step simultaneously provides use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is present in a preparation with at least one further adjuvant or and/or antigen.

8. (Currently amended) The method of claim 6 wherein use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is associated or combined with a physical or biological carrier.

9. (Currently amended) The method of claim 6 further comprising the step of providing, together

with use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein, is administered together with one or more anti-inflammatory, antiangiogenic, cytotoxic or immunomodulatory substances, or ligands or with antibodies, or is present with these in a preparation.

10. (Currently amended) The method of claim 6 further comprising the step of providing the animal or human with use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is present in a preparation which comprises further additives and excipients, in particular preservatives or stabilizers.

11. (Currently amended) The method of claim 6 wherein the antigen is present use as claimed in claim 1, characterized in that the vaccine which is accompanied by the adjuvant, in the form of peptides, proteins, DNA, polysaccharides, glycolipids or glycoproteins glucoproteins.

12. (New) The method of claim 1 wherein said providing an animal or human with an adjuvant step simultaneously provides at least one further adjuvant or antigen.

13. (New) The method of claim 1 wherein the lipopeptide or lipoprotein is associated or combined with a physical or biological carrier.

14. (New) The method of claim 1 further comprising the step of providing, together with the lipopeptide or lipoprotein, one or more anti-inflammatory, antiangiogenic, cytotoxic or immunomodulatory substances, ligands or antibodies.

15. (New) The method of claim 1 further comprising the step of providing the animal or human with further additives and excipients.

16. (New) The method of claim 1 wherein the antigen is present in the form of peptides, proteins, DNA, polysaccharides, glycolipids or glucoproteins.